Novel drug therapy lowers antibodies in kidney transplant patients
from By Lynn Hetzler
A new preoperative drug therapy may reduce antibodies in kidney patients better than using traditional methods, according to a three-year clinical trial led by University of Cincinnati transplant researchers. The novel approach may increase patients' candidacy for kidney transplantation and decrease the chances of rejection. The study, entitled "Prospective Iterative Trial of Proteasome Inhibitor-Based Desensitization" and published in the latest issue of American Journal of Transplantation, shows promise.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063